Drugs / NNC0560-0004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06133270 | Nov 2023 → Jul 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0560-0004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06133270 ↗ |
| Route | Oral | “Oral administration (taken through the mouth)” NCT06133270 ↗ |